Structure Therapeutics (GPCR) Cash from Financing Activities (2022 - 2026)
Quarterly Cash from Financing Activities fell 315.33% to -$1.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $760.0 million through Mar 2026, up 47.46% year-over-year, with the annual reading at $762.5 million for FY2025, 47.99% up from the prior year.
Structure Therapeutics' Cash from Financing Activities history spans 5 years, with the latest figure at -$1.7 million for Q1 2026.
- Cash from Financing Activities came in at -$1.7 million for Q1 2026, down from $705.0 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $705.0 million in Q4 2025 to a low of -$1.7 million in Q1 2026.
- The 5-year median for Cash from Financing Activities is $615000.0 (2024), against an average of $103.3 million.
- Year-over-year, Cash from Financing Activities soared 173400.67% in 2024 and then crashed 315.33% in 2026.
- Structure Therapeutics' Cash from Financing Activities stood at -$316000.0 in 2022, then skyrocketed by 89223.1% to $281.6 million in 2023, then tumbled by 99.78% to $615000.0 in 2024, then skyrocketed by 114532.03% to $705.0 million in 2025, then crashed by 100.25% to -$1.7 million in 2026.
- Per Business Quant, the three most recent readings for GPCR's Cash from Financing Activities are -$1.7 million (Q1 2026), $705.0 million (Q4 2025), and $56.2 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | 7.00 Mn |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | -600,000.00 |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | 53,000.00 |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | -538.80 Mn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | -802.20 Mn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 15.71 Mn |
| 10 | Structure Therapeutics | 8.43 Bn | 8.43 Bn | - | -1.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.74 Mn |
| Mar 31, 2026 | -1.74 Mn |
| Dec 31, 2025 | 704.99 Mn |
| Dec 31, 2025 | 704.99 Mn |
| Sep 30, 2025 | 56.20 Mn |
| Sep 30, 2025 | 56.20 Mn |
| Jun 30, 2025 | 517,000.00 |
| Jun 30, 2025 | 517,000.00 |
| Mar 31, 2025 | 809,000.00 |
| Mar 31, 2025 | 809,000.00 |
| Dec 31, 2024 | 615,000.00 |
| Dec 31, 2024 | 615,000.00 |
| Sep 30, 2024 | -757,000.00 |
| Sep 30, 2024 | -757,000.00 |
| Jun 30, 2024 | 514.70 Mn |
| Jun 30, 2024 | 514.70 Mn |
| Mar 31, 2024 | 702,000.00 |
| Mar 31, 2024 | 702,000.00 |
| Dec 31, 2023 | 281.63 Mn |
| Dec 31, 2023 | 281.63 Mn |
| Sep 30, 2023 | 473,000.00 |
| Sep 30, 2023 | 473,000.00 |
| Jun 30, 2023 | -297,000.00 |
| Jun 30, 2023 | -297,000.00 |
| Mar 31, 2023 | 169.73 Mn |
| Mar 31, 2023 | 169.73 Mn |
| Dec 31, 2022 | -316,000.00 |
| Dec 31, 2022 | -316,000.00 |
| Sep 30, 2022 | -259,000.00 |
| Sep 30, 2022 | -259,000.00 |
| Jun 30, 2022 | 31.04 Mn |
| Jun 30, 2022 | 31.04 Mn |
| Mar 31, 2022 | -1.45 Mn |
| Mar 31, 2022 | -1.45 Mn |